pharmaceutical industry | The Lund Report

Heart Drug Spotlights Troubling Trends In Drug Marketing

A company is marketing a drug intended as a preventive for people at risk for heart disease with stunning statistics but has not yet released details of its study.

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.

By:

Shefali Luthra

Walden A Top Recipient In Millions Funneled By Pharma To Lawmakers

Greg Walden, Oregon's only Republican in Congress, was one of two lawmakers who received more than $200,000 from pharmaceutical companies since January 2017.

Before the midterm elections heated up, dozens of drugmakers had already poured about $12 million into the war chests of hundreds of members of Congress.

By:

Emmarie Huetteman and Sydney Lupkin

Pharma’s Promises to Curb Drug Prices Have Been Heard Before

Companies have promised to curb prices in the past but consumers have not seen any relief.

Prescription drug prices were soaring. Angry policymakers swore they’d take action. Pharma giant Merck responded by promising to address the problem voluntarily, vowing to keep price increases under the overall rate of inflation.

By:

Jay Hancock and Sarah Jane Tribble